Your browser doesn't support javascript.
loading
[Coagulation activity of circulating membrane microparticles in patients with cardiovascular diseases]. / Koaguliatsionnaia aktivnost' tsirkuliruiushchikh membrannykh mikrochastits u patsientov s serdechno-sosudistymi zabolevaniiami.
Antonova, O A; Golubeva, N V; Yakushkin, V V; Zyuryaev, I T; Krivosheeva, E N; Komarov, A L; Martynyuk, T V; Mazurov, A V.
Afiliación
  • Antonova OA; National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow, Russia.
  • Golubeva NV; National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow, Russia.
  • Yakushkin VV; National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow, Russia.
  • Zyuryaev IT; National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow, Russia.
  • Krivosheeva EN; National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow, Russia.
  • Komarov AL; National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow, Russia.
  • Martynyuk TV; National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow, Russia.
  • Mazurov AV; National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow, Russia.
Biomed Khim ; 68(4): 288-296, 2022 Aug.
Article en Ru | MEDLINE | ID: mdl-36005847
Membrane microparticles (MP) are released by activated or damaged cells and are able to accelerate blood clotting (coagulation). MP possess coagulation activity since all of them contain on their surface phosphatidylserine (PS), a substrate for the assembly of coagulation complexes, and some of them tissue factor (TF), the primary initiator of coagulation cascade reactions. We compared the coagulation activity and amount of MP in the blood of healthy donors (n=34) and patients with myocardial infarction (MI) (n=32), advanced atherosclerosis (AA) (n=32) and idiopathic pulmonary arterial hypertension (IPAH) (n=19). Total MP fraction was obtained from blood plasma by sedimentation at 20000 g, 30 min. The coagulation activity of PM isolated from 100 µl of donor and patient plasma was determined using a modified recalcification test. MP were added to substrate plasma devoid of endogenous MF, plasma was recalcified, and clotting was recorded by changes in optical density (A450), determining lag phase (min) and maximum rate (Vmax, %A450/min). MP were counted by flow cytometry as PS+ particles (lactadgerin-FITC staining) smaller than 1 µm and their concentration was expressed as 105 MP/µl plasma. MP in all patient groups accelerated plasma clotting more effectively than donor MP. Lag phase compared with donors (11.8 [11.0-13.1] median and interquartile range) was shorter in patients with AA (8.8 [7.0-10.3], p.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Micropartículas Derivadas de Células Límite: Humans Idioma: Ru Revista: Biomed Khim Año: 2022 Tipo del documento: Article País de afiliación: Rusia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Micropartículas Derivadas de Células Límite: Humans Idioma: Ru Revista: Biomed Khim Año: 2022 Tipo del documento: Article País de afiliación: Rusia